Model systems for the study of human norovirus biology

Future Virology

Volumn 4, Issue 4, 2009, Pages 353-367

  Vashist, Surender ^a   Balley, Dalan ^a   Putics, Akos ^a   Goodfellow, Ian ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Animal models; Antiviral; Calicivirus; Gastroenteritis; Norwalk virus; PPMO; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; GAMMA INTERFERON; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; CALICIVIRUS; GENE SEQUENCE; HUMAN; IN VITRO STUDY; LAGOVIRUS; NONHUMAN; NOROVIRUS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; SAPOVIRUS; TULANE VIRUS; VESIVIRUS; VIRION; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTION; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALIA; CALICIVIRIDAE; NOROVIRUS; NORWALK VIRUS; RNA VIRUSES;

EID: 70350102886     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.18     Document Type: Review

References (119)

1. Kosek M, Bern C, Guerrant RL: The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull. World Health Organ. 81, 197-204 (2003).
2. Fankhauser RL, Noel JS, Monroe SS, Ando T, Glass RI: Molecular epidemiology of 'Norwalk-like viruses' in outbreaks of gastroenteritis in the United States. J. Infect. Dis. 178(6), 1571-1578 (1998).
3. Gallimore CI, Green J, Richards AF et al.: Methods for the detection and characterisation of noroviruses associated with outbreaks of gastroenteritis: outbreaks occurring in the north-west of England during two norovirus seasons. J. Med. Virol. 73(2), 280-288 (2004).
4. Svraka S, Duizer E, Vennema H et al.: Etiological role of viruses in outbreaks of acute gastroenteritis in The Netherlands from 1994 through 2005. J. Clin. Microbiol. 45(5), 1389-1394 (2007).
5. Lopman BA, Reacher MH, Van Duijnhoven Y, Hanon FX, Brown D, Koopmans M: Viral gastroenteritis outbreaks in Europe, 1995-2000. Emerg. Infect. Dis. 9(1), 90-96 (2003).
6. Lopman BA, Brown DW, Koopmans M: Human caliciviruses in Europe. J. Clin. Virol. 24(3), 137-160 (2002).
7. Turcios-Ruiz RM, Axelrod P, St John K et al.: Outbreak of necrotizing enterocolitis caused by norovirus in a neonatal intensive care unit. J. Pediatr. 153(3), 339-344 (2008).
8. Chen SY, Tsai CN, Lai MW et al.: Norovirus infection as a cause of diarrhea-associated benign infantile seizures. Clin. Infect. Dis. 48(7), 849-855 (2009).
9. Girard MP, Steele D, Chaignat CL, Kieny MP: A review of vaccine research and development: human enteric infections. Vaccine 24(15), 2732-2750 (2006).
10. Kapikian AZ, Wyatt RG, Dolin R, Thornhill TS, Kalica AR, Chanock RM: Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J. Virol. 10(5), 1075-1081 (1972).
11. Dolin R, Blacklow NR, DuPont H et al.: Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. J. Infect. Dis. 123(3), 307-312 (1971).
12. Atmar RL, Opekun AR, Gilger MA et al.: Norwalk virus shedding after experimental human infection. Emerg. Infect. Dis. 14(10) 1553-1557 (2008).
13. Kurtz JB, Lee TW, Pickering D: Astrovirus associated gastroenteritis in a children's ward. J. Clin. Pathol. 30(10), 948-952 (1977).
14. Richmond SJ, Caul EO, Dunn SM, Ashley CR, Clarke SK, Seymour NR: An outbreak of gastroenteritis in young children caused by adenoviruses. Lancet 1(8127), 1178-1181 (1979).
15. Bishop LDH: Complete transcription by the transcriptase of VSV. J. Virol. 7, 486-490 (1971).
16. Dolin R, Blacklow NR, DuPont H et al.: Biological properties of Norwalk agent of acute infectious nonbacterial gastroenteritis. Proc. Soc. Exp. Biol. Med. 140(2), 578-583 (1972).
17. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MPG, Estes MK: Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85(1), 79-87 (2004).
18. Guix S, Asanaka M, Katayama K et al.: Norwalk virus RNA is infectious in mammalian cells. J. Virol. 81(22), 12238-12248 (2007).
19. Straub TM, Höner zu Bentrup K, Orosz-Coghlan P et al.: In vitro cell culture infectivity assay for human noroviruses. Emerging Infect. Dis. 13(3), 396-403 (2007).
20. Nickerson CA, Goodwin TJ, Terlonge J et al.: Three-dimensional tissue assemblies: novel models for the study of Salmonella enterica Serovar Typhimurium pathogenesis. Infect. Immun. 69(11), 7106-7120 (2001).
21. Unsworth BR, Lelkes PI: Growing tissues in microgravity. Nat. Med. 4(8), 901-907 (1998).
22. Hammond TG, Hammond JM: Optimized suspension culture: the rotating-wall vessel. Am. J. Physiol. Renal. Physiol. 281(1), F12-F25 (2001).
23. Murakami K, Ishii K, Ishihara Y et al.: Production of infectious hepatitis C virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral RNA of genotype 1b. Virology 351(2), 381-392 (2006).
24. Marionneau S, Ruvoen N, Le Moullac-Vaidye B et al.: Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 122(7), 1967-1977 (2002).
25. Chang KO, Sosnovtsev SV, Belliot G, King AD, Green KY: Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 353(2), 463-473 (2006).
26. Chang KO, George DW: Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. J. Virol. 81(22), 12111-12118 (2007).
27. Bok K, Cavanaugh VJ, Matson DO et al.: Inhibition of norovirus replication by morpholino oligomers targeting the 5′-end of the genome. Virology 380(2), 328-337 (2008).
28. Jiang X, Wang M, Graham DY, Estes MK: Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66(11), 6527-6532 (1992).
29. Green KY, Kapikian AZ, Valdesuso J, Sosnovtsev S, Treanor JJ, Lew JF: Expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calicivirus. J. Clin. Microbiol. 35(7), 1909-1914 (1997).
30. Taube S, Kurth A, Schreier E: Generation of recombinant norovirus-like particles (VLP) in the human endothelial kidney cell line 293T. Arch. Virol. 150(7), 1425-1431 (2005).
31. Baric RS, Yount B, Lindesmith L et al.: Expression and self-assembly of Norwalk virus capsid protein from Venezuelan equine encephalitis virus replicons. J. Virol. 76(6), 3023-3030 (2002).
32. Huang Z, Elkin G, Maloney BJ et al.: Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 23(15), 1851-1858 (2005).
33. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ: Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182(1), 302-305 (2000).
34. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS: Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J. Virol. 76(23), 12335-12343 (2002).
35. Harrington PR, Vinje J, Moe CL, Baric RS: Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. J. Virol. 78(6), 3035-3045 (2004).
36. Wobus CE, Thackray LB, Virgin HW 4th: Murine norovirus: a model system to study norovirus biology and pathogenesis. J. Virol. 80(11), 5104-5112 (2006).
37. Wobus CE, Karst SM, Thackray LB et al.: Replication of norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2(12), e432 (2004).
38. Parwani AV, Flynn WT, Gadfield KL, Saif LJ: Serial propagation of porcine enteric calicivirus in a continuous cell line. Effect of medium supplementation with intestinal contents or enzymes. Arch. Virol. 120(1-2), 115-122 (1991).
39. Kapikian, A Z: Overview of viral gastroenteritis. Arch. Virol. Suppl. 12, 7-19 (1996).
40. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK: Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology 117(1), 40-48 (1999).
41. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS: Cellular and humoral immunity following Snow Mountain virus challenge. J. Virol. 79(5), 2900-2909 (2005).
42. Rockx B, Baric RS, de Grijs I, Duizer E, Koopmans MP: Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J. Med. Virol. 77(3), 439-446 (2005).
43. Atmar RL, Estes MK: Diagnosis of noncultivatable gastroenteritis viruses, the human caliciviruses. Clin. Microbiol. Rev. 14(1), 15-37 (2001).
44. Katayama K, Shirato-Horikoshi H, Kojima S et al.: Phylogenetic analysis of the complete genome of 18 Norwalk-like viruses. Virology 299(2), 225-239 (2002).
45. Bull RA, Tanaka MM, White PA: Norovirus recombination. J. Gen. Virol. 88(Pt 12), 3347-3359 (2007).
46. Lindesmith CL, Donaldson EF, Lobue AD et al.: Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5(2), e31 (2008).
47. Troeger H, Loddenkemper C, Schneider T et al.: Structural and functional changes of the duodenum in human norovirus infection. Gut (2008) (Epub ahead of print).
48. Scipioni A, Mauroy A, Vinje J, Thiry E: Animal noroviruses. Vet. J. 178(1), 32-45 (2008).
49. Rockx BH, Bogers WM, Heeney JL, van Amerongen G, Koopmans MP: Experimental norovirus infections in nonhuman primates. J. Med. Virol. 75(2), 313-320 (2005).
50. Farkas T, Sestak K, Wei C, Jiang X: Characterization of a rhesus monkey calicivirus representing a new genus of Caliciviridae. J. Virol. 82(11), 5408-5416 (2008).
51. Wei C, Farkas T, Sestak K, Jiang X: Recovery of infectious virus by transfection of in vitro-generated RNA from Tulane calicivirus cDNA. J. Virol. 82(22), 11429-11436 (2008).
52. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HW 4th: STAT1-dependent innate immunity to a Norwalk-like virus. Science 299(5612), 1575-1578 (2003).
53. Mumphrey SM, Changotra H, Moore TN et al.: Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. J. Virol. 81(7), 3251-3263 (2007).
54. Bailey D, Thackray LB, Goodfellow IG: A single amino acid substitution in the murine norovirus capsid protein is sufficient for attenuation in vivo. J. Virol. 82(15), 7725-7728 (2008).
55. McCartney SA, Thackray LB, Gitlin L, Gilfillan S, Virgin HW, Colonna M: MDA-5 recognition of a murine norovirus. PLoS Pathog. 4(7), e1000108 (2008).
56. Chachu KA, LoBue AD, Strong DW, Baric RS, Virgin HW: Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog. 4(12), e1000236 (2008).
57. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS: Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral and mucosal immune responses protect against murine norovirus challenge. J. Virol. 83(7), 3212-3227 (2009).
58. Hsu CC, Riley LK, Wills HM, Livingston RS: Persistent infection with and serologic cross-reactivity of three novel murine noroviruses. Comp. Med. 56(4), 247-251 (2006).
59. Hsu CC, Riley LK, Livingston RS: Molecular characterization of three novel murine noroviruses. Virus Genes 34(2), 147-155 (2007).
60. Thackray LB, Wobus CE, Chachu KA et al.: Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence. J. Virol. 81(19), 10460-10473 (2007).
61. Khan RR, Lawson AD, Minnich LL et al.: Gastrointestinal norovirus infection associated with exacerbation of inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 48(3), 328-333 (2009).
62. Lencioni KC, Seamons A, Treuting PM, Maggio-Price L, Brabb T: Murine norovirus: an intercurrent variable in a mouse model of bacteria-induced inflammatory bowel disease. Comp. Med. 58(6), 522-533 (2008).
63. Wang QH, Souza M, Funk JA, Zhang W, Saif LJ: Prevalence of noroviruses and sapoviruses in swine of various ages determined by reverse transcription-PCR and microwell hybridization assays. J. Clin. Microbiol. 44(6), 2057-2062 (2006).
64. Wang QH, Costantini V, Saif LJ: Porcine enteric caliciviruses: genetic and antigenic relatedness to human caliciviruses, diagnosis and epidemiology. Vaccine 25(30), 5453-5466 (2007).
65. Cheetham S, Souza M, Meulia T, Grimes S, Han MG, Saif LJ: Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J. Virol. 80(21), 10372-10381 (2006).
66. Guo M, Hayes J, Cho KO, Parwani AV, Lucas LM, Saif LJ: Comparative pathogenesis of tissue culture-adapted and wild-type Cowden porcine enteric calicivirus (PEC) in gnotobiotic pigs and induction of diarrhea by intravenous inoculation of wild-type PEC. J. Virol. 75(19), 9239-9251 (2001).
67. Souza M, Cheetham SM, Azevedo MS, Costantini V, Saif LJ: Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). J. Virol. 81(17), 9183-9192 (2007).
68. Oliver SL, Dastjerdi AM, Wong S et al.: Molecular characterization of bovine enteric caliciviruses: a distinct third genogroup of noroviruses (Norwalk-like viruses) unlikely to be of risk to humans. J. Virol. 77(4), 2789-2798 (2003).
69. Wolf S, Williamson W, Hewitt J et al.: Molecular detection of norovirus in sheep and pigs in New Zealand farms. Vet. Microbiol 133(1-2), 184-189 (2008).
70. Bae J, Schwab KJ: Evaluation of murine norovirus, feline calicivirus, poliovirus, and MS2 as surrogates for human norovirus in a model of viral persistence in surface water and groundwater. Appl. Environ. Microbiol. 74(2), 477-484 (2008).
71. Buckow R, Isbarn S, Knorr D, Heinz V, Lehmacher A: Predictive model for inactivation of feline calicivirus, a norovirus surrogate, by heat and high hydrostatic pressure. Appl. Environ. Microbiol. 74(4), 1030-1038 (2008).
72. Topping JR, Schnerr H, Haines J et al.: Temperature inactivation of feline calicivirus vaccine strain FCV F-9 in comparison with human noroviruses using an RNA exposure assay and reverse transcribed quantitative real-time polymerase chain reaction-A novel method for predicting virus infectivity. J. Virol. Methods 156(1-2), 89-95 (2009).
73. Sosnovtsev S, Green KY: RNA transcripts derived from a cloned full-length copy of the feline calicivirus genome do not require VPg for infectivity. Virology 210(2), 383-390 (1995).
74. Thiel HJ, Konig M: Caliciviruses: an overview. Vet. Microbiol. 69(1-2), 55-62 (1999).
75. McIntosh MT, Behan SC, Mohamed FM et al.: A pandemic strain of calicivirus threatens rabbit industries in the Americas. Virol. J. 4, 96 (2007).
76. Capucci L, Fusi P, Lavazza A, Pacciarini ML, Rossi C: Detection and preliminary characterization of a new rabbit calicivirus related to rabbit hemorrhagic disease virus but nonpathogenic. J. Virol. 70(12), 8614-8623 (1996).
77. Le Pendu J, Ruvoen-Clouet N, Kindberg E, Svensson L: Mendelian resistance to human norovirus infections. Semin. Immunol. 18(6), 375-386 (2006).
78. Tamura M, Natori K, Kobayashi M, Miyamura T, Takeda N: Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane. J. Virol. 78(8), 3817-3826 (2004).
79. Rydell GE, Nilsson J, Rodriguez-Diaz J et al.: Human noroviruses recognize sialyl Lewis x neoglycoprotein. Glycobiology 19(3), 309-320 (2009).
80. Chaudhry Y, Nayak A, Bordeleau ME et al.: Caliciviruses differ in their functional requirements for eIF4F components. J. Biol. Chem. 281, 25315-25325 (2006).
81. Daughenbaugh KF, Fraser CS, Hershey JW, Hardy ME: The genome-linked protein VPg of the Norwalk virus binds eIF3, suggesting its role in translation initiation complex recruitment. EMBO J. 22(11), 2852-2859 (2003).
82. Goodfellow I, Chaudhry Y, Gioldasi I et al.: Calicivirus translation initiation requires an interaction between VPg and eIF4E. EMBO Reports 6(10), 968-972 (2005).
83. Daughenbaugh KF, Wobus CE, Hardy ME: VPg of murine norovirus binds translation initiation factors in infected cells. Virol. J. 3, 33 (2006).
84. Chang KO, Sosnovtsev SS, Belliot G, Wang Q, Saif LJ, Green KY: Reverse genetics system for porcine enteric calicivirus, a prototype sapovirus in the Caliciviridae. J. Virol. 79(3), 1409-1416 (2005).
85. Chang KO, Sosnovtsev SV, Belliot G, Kim Y, Saif LJ, Green KY: Bile acids are essential for porcine enteric calicivirus replication in association with down-regulation of signal transducer and activator of transcription 1. Proc. Natl Acad. Sci. USA 101(23), 8733-8738 (2004).
86. Liu G, Ni Z, Yun T et al.: A DNA-launched reverse genetics system for rabbit hemorrhagic disease virus reveals that the VP2 protein is not essential for virus infectivity. J. Gen. Virol. 89(Pt 12), 3080-3085 (2008).
87. Liu GQ, Ni Z, Yun T et al.: Rabbit hemorrhagic disease virus poly(A) tail is not essential for the infectivity of the virus and can be restored in vivo. Arch. Virol. 153(5), 939-944 (2008).
88. Morales M, Barcena J, Ramirez MA, Boga JA, Parra F, Torres JM: Synthesis in vitro of rabbit hemorrhagic disease virus subgenomic RNA by internal initiation on (-) sense genomic RNA: mapping of a subgenomic promoter. J. Biol. Chem. 279(17), 17013-17018 (2004).
89. Meyers G: Translation of the minor capsid protein of a calicivirus is initiated by a novel termination-dependent reinitiation mechanism. J. Biol. Chem. 278(36), 34051-34060 (2003).
90. Meyers G: Characterization of the sequence element directing translation reinitiation in RNA of the calicivirus rabbit hemorrhagic disease virus. J. Virol. 81(18), 9623-9632 (2007).
91. Willcocks MM, Carter MJ, Roberts LO: Cleavage of eukaryotic initiation factor eIF4G and inhibition of host-cell protein synthesis during feline calicivirus infection. J. Gen. Virol. 85(Pt 5), 1125-1130 (2004).
92. Makino A, Shimojima M, Miyazawa T, Kato K, Tohya Y, Akashi H: Junctional adhesion molecule 1 is a functional receptor for feline calicivirus. J. Virol. 80(9), 4482-4490 (2006).
93. Bhella D, Gatherer D, Chaudhry Y, Pink R, Goodfellow IG: Structural insights into calicivirus attachment and uncoating. J. Virol. 82(16), 8051-8058 (2008).
94. Karakasiliotis I, Chaudhry Y, Roberts LO, Goodfellow IG: Feline calicivirus replication: requirement for polypyrimidine tract-binding protein is temperature dependent. J. Gen. Virol. 87, 3339-3347 (2006).
95. Gutierrez-Escolano AL, Brito ZU, del Angel RM, Jiang X: Interaction of cellular proteins with the 5′ end of Norwalk virus genomic RNA. J. Virol. 74(18), 8558-8562 (2000).
96. Gutierrez-Escolano AL, Vazquez-Ochoa M, Escobar-Herrera J, Hernandez-Acosta J: La, PTB, and PAB proteins bind to the 3′ untranslated region of Norwalk virus genomic RNA. Biochem. Biophys. Res. Commun. 311(3), 759-766 (2003).
97. Sandoval-Jaime C, Gutiérrez-Escolano A: Cellular proteins mediate 5′-3′ end contacts of Norwalk virus genomic RNA. Virology 387(2), 322 (2009).
98. Chaudhry Y, Skinner MA, Goodfellow IG: Recovery of genetically defined murine norovirus in tissue culture by using a fowlpox virus expressing T7 RNA polymerase. J. Gen. Virol. 88(Pt 8), 2091-2100 (2007).
99. Ward VK, McCormick CJ, Clarke IN et al.: Recovery of infectious murine norovirus using pol II-driven expression of full-length cDNA. Proc. Natl Acad. Sci. USA 104(26), 11050-11055 (2007).
100. Simmonds P, Karakasiliotis I, Bailey D, Chaudhry Y, Evans DJ, Goodfellow IG: Bioinformatic and functional analysis of RNA secondary structure elements among different genera of human and animal caliciviruses. Nucleic Acids Res. 36(8), 2530-2546 (2008).
101. Sosnovtsev SV, Belliot G, Chang KO et al.: Cleavage map and proteolytic processing of the murine norovirus nonstructural polyprotein in infected cells. J. Virol. 80(16), 7816-7831 (2006).
102. Bok K, Prikhodko VG, Green KY, Sosnovtsev SV: Apoptosis in murine norovirus-infected RAW264.7 cells is associated with downregulation of survivin. J. Virol. 83(8), 3647-3656 (2009).
103. Taube S, Perry JW, Yetming K et al.: Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses (MNV). J. Virol. 83(9), 4092-4101 (2009).
104. Asanaka M, Atmar RL, Ruvolo V, Crawford SE, Neill FH, Estes MK: Replication and packaging of Norwalk virus RNA in cultured mammalian cells. Proc. Natl Acad. Sci. USA 102(29), 10327-10332 (2005).
105. Moe CL, Christmas WA, Echols LJ, Miller SE: Outbreaks of acute gastroenteritis associated with Norwalk-like viruses in campus settings. J. Am. Coll. Health 50(2), 57-66 (2001).
106. Bucardo F, Nordgren J, Carlsson B et al.: Pediatric norovirus diarrhea in Nicaragua. J. Clin. Microbiol. 46(8), 2573-2580 (2008).
107. Gallimore CI, Lewis D, Taylor C, Cant A, Gennery A, Gray JJ: Chronic excretion of a norovirus in a child with cartilage hair hypoplasia (CHH). J. Clin. Virol. 30(2), 196-204 (2004).
108. Stein AD: Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers. Curr. Pharm. Des. 14(25), 2619-2634 (2008).
109. Smith AW, Iversen PL, O'Hanley PD et al.: Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection. Am. J. Vet. Res. 69(1), 23-32 (2008).
110. Graci JD, Cameron CE: Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16(1), 37-48 (2006).
111. Crotty S, Maag D, Arnold JJ et al.: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6(12), 1375-1379 (2000).
112. Crotty S, Cameron C, Andino R: Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. 80(2), 86-95 (2002).
113. Graci JD, Cameron CE: Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol. 3(6), 553-566 (2008).
114. Belliot G, Sosnovtsev SV, Mitra T, Hammer C, Garfield M, Green KY: In vitro proteolytic processing of the MD145 norovirus ORF1 nonstructural polyprotein yields stable precursors and products similar to those detected in calicivirus-infected cells. J. Virol. 77(20), 10957-10974 (2003).
115. Nakamura K, Someya Y, Kumasaka T et al.: A norovirus protease structure provides insights into active and substrate binding site integrity. J. Virol. 79(21), 13685-13693 (2005).
116. Scheffler U, Rudolph W, Gebhardt J, Rohayem J: Differential cleavage of the norovirus polyprotein precursor by two active forms of the viral protease. J. Gen. Virol. 88(Pt 7), 2013-2018 (2007).
117. Ettayebi K, Hardy ME: Recombinant norovirus-specific scFv inhibit virus-like particle binding to cellular ligands. Virol. J. 5, 21 (2008).
118. Feng X, Jiang X: Library screen for inhibitors targeting norovirus binding to histo-blood group antigen receptors. Antimicrob. Agensts Chemother. 51(1), 324-331 (2007).
119. Changotra H, Jia Y, Moore TN et al.: Type I and type II interferons inhibit the translation of murine norovirus proteins. J. Virol. 83(11), 5683-5692 (2009).